Nexalin Technology Reports Compelling Clinical Trial Results in Brazil for Anxiety and Depression Treatment
Summary
Nexalin Technology announced successful completion of an 8-week clinical trial at the University of Sao Paulo evaluating its proprietary 15 mA, 77.5 Hz Deep Intracranial Frequency Stimulation platform in adults with generalized anxiety disorder and comorbid insomnia. The trial demonstrated a 77.8 percent anxiety response rate with rapid, large-magnitude improvements across anxiety, depression, insomnia, and quality of life that were maintained at 8-week follow-up. No serious adverse events, seizures, or manic switches were reported.
Why it matters
These results provide strong clinical validation for Nexalin's differentiated non-invasive deep-brain frequency stimulation approach at a time when global mental health needs are urgent and growing. The favorable tolerability profile combined with durable benefits across multiple symptom domains positions Nexalin's technology as a potentially breakthrough option for patients who have not responded adequately to pharmacological treatments.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial